Innate Pharma S.A. (NASDAQ:IPHA) Q4 2024 Earnings Conference Call March 27, 2025 9:00 AM ET Company Participants Henry Wheeler - VP, IR and Communications Jonathan Dickinson - CEO Yannis Morel - COO Sonia Quaratino - CMO Frederic Lombard - CFO Conference Call Participants Daina Graybosch - Leerink Partners Swayampakula Ramakanth - H.C. Wainwright Operator Hello, and welcome to the Innate Pharma Full Year 2024 Financial Results and Business Update. All lines have been placed on mute to prevent any background ...

Full Year 2024 Business Update and Financial Results 27 March 2024 Disclaimer on Forward-Looking Information and Risk Factors This document has been prepared by Innate Pharma S.A. (the "Company") solely for the purposes of a presentation to investors concerning the Company. This document is not to be reproduced by any person, nor to be distributed. This document contains forward-looking statements. The use of certain words, including "believe," "potential," "expect" and "will" and similar expressions, is in ...

I have my PhD in biochemistry and have worked for years analyzing clinical trials and biotech companies. It is my passion to educate everyone possible on the science behind the businesses that we invest in, and it's my mission to help you do your due diligence and not get burned by the pitfalls of investing in this space.Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wr ...

Group 1 - The author has a PhD in biochemistry and extensive experience analyzing clinical trials and biotech companies, emphasizing the importance of understanding the science behind investments in this sector [1] - The mission is to educate investors on conducting due diligence to avoid pitfalls in biotech investments [1] Group 2 - There is a potential for initiating a short position in IPHA through short-selling or purchasing put options within the next 72 hours [2] - The article expresses personal opinions and does not involve compensation from any mentioned companies [2]

Innate Pharma S.A. (NASDAQ:IPHA) Q3 2024 Earnings Conference Call November 13, 2024 8:00 AM ET Company Participants Henry Wheeler - Vice President, Investor Relations and Communications Jonathan Dickinson - Chief Executive Officer Sonia Quaratino - Chief Medical Officer Yannis Morel - Chief Operating Officer Frederic Lombard - Chief Financial Officer Arvind Sood - Executive Vice President U.S. Operations Conference Call Participants Daina Graybosch - Leerink Partners Rajan Sharma - Goldman Sachs Arthur He - ...

| --- | --- | --- | |-----------------------------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | Q3 2024 Business Update and | | | | Financial Results | | | | 13 November 2024 | | | | | | | Disclaimer on Forward-Looking Information and Risk Factors 2 This document has been prepared by Innate Pharma S.A. (the "Company") solely for the purposes of a presentation to investors concerning the Company. This document is not to be reproduced by any person, nor to be distributed. This document c ...

Financial Data and Key Metrics Changes - Revenue and other income for the first half of 2024 amounted to $12.3 million, primarily from collaboration and licensing agreements, and governmental funding for research of $4.1 million [22] - Operating expenses reached $38.7 million, with 75% related to R&D, which decreased by 5% to $29.1 million due to lower personnel and other R&D expenses [23] - Cash and cash equivalents totaled $102.1 million as of June 30, 2024, sufficient to fund operations until the end of 2025 [23] Business Line Data and Key Metrics Changes - The lead proprietary asset, lacutamab, is in development for T cell lymphoma, with topline data expected to be presented at ASH in December [4] - The ANKET platform continues to progress, with the lead candidate SAR443579 transitioning from Phase 1 to Phase 2, and IPH6501 continuing in Phase 1 [5] - The ADC asset IPH45 is progressing through Phase 1, targeting Nectin-4 [5][18] Market Data and Key Metrics Changes - The TELLOMAK trial for lacutamab in Cutaneous T Cell Lymphoma showed a global objective response rate of 16.8% and a median progression-free survival of 10.2 months [10] - The potential patient population for lacutamab in CTCL could expand from 1,500 to 5,000 with a proposed registration strategy for fast-to-market approval [11][12] Company Strategy and Development Direction - The company aims to create near-term value through lacutamab and longer-term value by leveraging antibody engineering capabilities [4] - The strategy includes building partnerships across the industry, as seen with monalizumab partnered with AstraZeneca [6] - The company is focused on developing innovative drug candidates with a strong pipeline of differentiated antibodies [4] Management's Comments on Operating Environment and Future Outlook - Management is engaged with the FDA on a proposed registration strategy for lacutamab, which could benefit from expedited approval programs [28] - The company is optimistic about the potential of its pipeline, with several first-in-class opportunities and a strong cash position to fund operations [24] Other Important Information - The company is celebrating its 25th anniversary and will host an investor meeting in New York on October 3 [25] - The termination of the partnership with Takeda was due to a strategic review on their side, with no significant data generated that would inform the ADC program [30] Q&A Session Summary Question: Insights on NeoCOAST-2 data and monalizumab's potential role - The NeoCOAST data shows encouraging efficacy for monalizumab, but further data is awaited as the trial is ongoing [26][28] Question: CEO appointment timeline and strategic decision-making - The process for appointing a permanent CEO is ongoing, and strategic decisions will be made by the Board with the CEO in place [31][44] Question: Details on PACIFIC 9 interim analysis - No additional details can be provided regarding the interim analysis; the trial is continuing based on the IDMC's recommendation [33] Question: Timing for regulatory interactions with lacutamab - Regulatory interactions for lacutamab are expected in the fourth quarter of this year [34][35] Question: Progress in PTCL indication for lacutamab - The KILT Phase 2 trial for lacutamab in PTCL is ongoing and expected to report data late next year [43]

INNATE PHARMA SA HALF-YEAR FINANCIAL REPORT JUNE 30, 2024 INNATE PHARMA S.A. French société anonyme governed by an Executive Board and a Supervisory Board with a share capital of 4,049,171.60 euros composed of 80,969,357 ordinary shares, and 14,075 preferred shares with a nominal value of 0.05 euros each Registered office: 117, Avenue de Luminy, F-13009 Marseille, France Registered with the Company and Trade Register of Marseille under number 424 365 336 The following interim condensed consolidated financia ...

Innate Pharma S.A. (NASDAQ:IPHA) Q1 2024 Results Conference Call May 14, 2024 8:00 AM ET | --- | |-------------------------------------------------| | | | Henry Wheeler - Head, Investor Relations | | Herve Brailly - Interim Chief Executive Officer | | Sonia Quaratino - Chief Medical Officer | | Yannis Morel - Chief Operating Officer | | Arvind Sood - EVP, U.S. Operations | | Frederic Lombard - Chief Financial Officer | | Conference Call Participants | | Daina Graybosch - Leerink Partners | | Yigal Nochomovi ...

Innate Pharma S.A. Sponsored ADR (IPHA) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Indiv ...